Patents Assigned to Georgetown University
  • Treatment of pulmonary disorders with retinoic acid or other retinoids by inducing formation of gas-exchange units (alveoli)
    Patent number: 6277890
    Abstract: This invention relates to the use of retinoic acid, its esters and analogues thereof for enhancing alveolar function or development. The method comprises administration of a composition containing an alveoli formation-inducing effective amount of a retinoic acid, its esters and analogues of retinoic acid.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: August 21, 2001
    Assignee: Georgetown University School of Medicine
    Inventors: Gloria Massaro, Donald Massaro
  • Intermediates useful for the synthesis of huperzine A
    Patent number: 6271379
    Abstract: Intermediates useful for the synthesis of huperzine A represented by the structures below, and methods for their synthesis, wherein: R1 is lower alkyl, benzyl, or substituted benzyl; X is a suitable leaving group; Y is an electron withdrawing group that can subsequently be converted into an amino group; one broken line is present as a carbon—carbon bond and the other broken line is absent, where the broken line forms an unconjugated carbon—carbon double bond, which double bond may be endocyclic whereby n is 3 or the double bond may be exocyclic whereby n is 2.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: August 7, 2001
    Assignee: Georgetown University
    Inventors: Werner Tückmantel, Alan P. Kozikowski
  • Inhibition of an FGF-binding protein using ribozymes
    Patent number: 6245748
    Abstract: Increased expression of a secreted FGF-binding protein (FGF-BP) occurs in certain autoimmune and malignant disease conditions. It is found, for example, that tumor secretions of FGF-BP results in mobilization and activation of locally-stored FGFs that can serve as an angiogenic switch molecule. Furthermore, it has been found that in an animal model of multiple sclerosis (MS), the exacerbation of the disease is accompanied by increased FGF-BP. Using ribozymes, it is possible to cause cleavage of the FGF-BP mRNA. Hence, administration of ribozymes which cleave the FGF-BP mRNA in sufficient amounts to inhibit disease processes triggered by FGF-BP is appropriate.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: June 12, 2001
    Assignee: Georgetown University
    Inventors: Anton Wellstein, Frank Czubayko
  • Bicyclic metabotropic glutamate receptor ligands
    Patent number: 6204292
    Abstract: The present invention provides bicyclic metabotropic glutamate receptor ligands, as well as compositions comprising such ligands, and and methods for their use.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: March 20, 2001
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Darryl Hugh Steensma, Werner Tueckmantel, Gian Luca Araldi
  • Bi- and tri-cyclic aza compounds and their uses
    Patent number: 6150376
    Abstract: The present invention provides tropane-derived monoamine neurotransmitter re-uptake inhibitors which predictably exhibit selectivity for either the serotonin or dopamine transporter, pharmaceutical compositions thereof and methods for their use. The serotonin-selective re-uptake inhibitors are particularly useful for treating neurological disorders associated with the serotonergic neural system of the brain, such as depression, with significantly reduced side-effects. The dopamine-selective re-uptake inhibitors are particularly useful for treating disorders associated with dopamine re-uptake and/or acetylcholine release.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: November 21, 2000
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Miles P. Smith
  • Heregulin antagonists and methods for their use
    Patent number: 6143740
    Abstract: The invention provides a method of inhibiting cancer cell growth, and thereby of treating cancer comprising administering to a mammal afflicted with cancer an effective amount of the compound of formula (I), wherein the variables of R.sub.1, and R.sub.2 have the meanings defined in the specification. The present invention also provides novel compounds of formula (I) as well as novel pharmaceutical compositions and intermediates useful for preparing compounds of formula (I). The figure illustrates the structure and binding activity of compounds of the invention and some of the rifamycin analogs.______________________________________ ##STR1##______________________________________ Compounds R.sub.1 = ______________________________________ A1 --OH A2 --OH A3 --OH A4 --OH A5 --OH A6 --OH A7 --OH - A8 ##STR2## ______________________________________ Compounds R.sub.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: November 7, 2000
    Assignee: Georgetown University
    Inventors: Dajun Yang, Shaomeng Wang, Alan P. Kozikowski, Marc E. Lippman
  • Progesterone analogs to reverse multidrug resistance
    Patent number: 6143737
    Abstract: The present invention is directed to compounds of formula I ##STR1## wherein the substituents are as defined in the specification. Also disclosed are compositions and method of use of the compounds.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: November 7, 2000
    Assignee: Georgetown University
    Inventors: Robert Clarke, Abdel H. Talebian, Alem Ghiorghis, Fabio Leonessa, Charles Hammer
  • Replication-competent Herpes simplex virus mediates destruction of neplastic cells
    Patent number: 6139834
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .gamma.34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: October 31, 2000
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Immobilization of membrane receptor on HPLC
    Patent number: 6139735
    Abstract: This invention provides a immobilized receptors on supports in liquid chromatographic systems. The method of the invention provides means of evaluating the attachment of agents to receptors comprising the steps of:(a) immobilizing receptors on artificial membrane supports in a column,(b) exposing the supports with the receptors to test agents at varying concentrations in a liquid chromatographic system,(c) eluting the test agent from the column, and(d) evaluating the elution profile of the test materials from the column.Using this method, it is possible to evaluate the interaction of the test agent with the receptor. Following elution, it is possible to directly determine molecular structure by passing the elute through other testing devices such as a mass spectrometer.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: October 31, 2000
    Assignee: Georgetown University
    Inventors: Irving Wainer, Yanxiao Zhang
  • Liposomes containing oligonucleotides
    Patent number: 6126965
    Abstract: It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5'-GTGCTCCATTGATGC-3' (seq. #1) wherein only the end bases are phosphorylated is a preferred embodiment. Antisense sequences of up to 40 bases which containing this sequence may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: October 3, 2000
    Assignee: Georgetown University School of Medicine
    Inventors: Usha Kasid, Prafulla Gokhale, Anatoly Dritschilo, Aquilur Rahman
  • Histidine kinase two-component in Candida albicans
    Patent number: 6120999
    Abstract: The present invention relates to a histidine kinase, two-component gene (CaHK1) from Candida albicans. CaHK1 encodes a 2471 amino acid protein with an estimated molecular mass of 281.8 kDa. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates agonists and antagonists and to screening methods for identifying agonists and antagonists of CaHK1 polypeptide activity. The invention additionally relates to diagnostic methods for detecting CaHK1 nucleic acids, polypeptides, and antibodies in a biological sample. The present invention further relates to novel antagonists and vaccines for the prevention or attenuation of infection by Candida albicans.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: September 19, 2000
    Assignees: Human Genome Sciences, Inc., The Georgetown University
    Inventors: Antonio Jose C. Abad, Gil H. Choi, Richard A. Calderone
  • Extracts of Salvia species having antiviral activity
    Patent number: 6117903
    Abstract: This invention provides extracts of Salvia species essentially consisting of that fraction from a Salvia that precipitates from aqueous solution at pH .ltoreq.3, said precipitate having the property such that it is is essentially fully dissolved in aqueous solution at pH 6, with solubility beginning to be readily observable at about pH 4, said extract having a molecular weight of .ltoreq.3500 datons. A preferred embodiment of the invention provides active agents having a molecular weight of .ltoreq.1000 daltons.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: September 12, 2000
    Assignee: Georgetown University
    Inventors: Myun K. Han, Paul Lee
  • Method for treating essential hypertension
    Patent number: 6096759
    Abstract: This invention relates to the treatment of essential hypertension by administration of anti-hypertensive effective amounts of 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (tempol).
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: August 1, 2000
    Assignee: Georgetown University
    Inventor: Christopher S. Wilcox
  • Monoclonal antibody to an 80 kda protease
    Patent number: 6077938
    Abstract: Compositions of the instant invention comprise a monoclonal antibody designated as 21-9 which binds selectively with an 80 kDa matrix-degrading proteinase having an average molecular weight of about 80 kDa, which is active in the presence of Ca.sup.2, Mg.sup.2+ and Mn.sup.2+.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: June 20, 2000
    Assignee: Georgetown University
    Inventors: Robert B. Dickson, Chen-Yong Lin
  • Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
    Patent number: 6077661
    Abstract: The invention relates generally to the quantitation of virus and viral nucleic acid. The invention relates to methods for quantitating an amount of virus present in a sample, comprising introducing into the sample a composition comprising a genetically tagged viral nucleic acid, isolating said wild type and said tagged nucleic acid, and quantitating said wild type and said tagged nucleic acid. The invention also relates to genetically tagged retroviral nucleic acid comprising a tag sequence, including insertions and deletions.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: June 20, 2000
    Assignee: Georgetown University
    Inventors: Venkatachala Natarajan, Norman P. Salzman
  • Compounds obtained from salvia species having antiviral activity
    Patent number: 6043276
    Abstract: Compositions are provided containing molecules having at least one moiety from .beta.-(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid, which are found in extracts from the plant genus Salvia, said moieties being of the formula: ##STR1## the active agents having a molecular weight of at least 190 daltons. A class of preferred agents are those which are conjugated to form dimers, trimers, tetramers and larger polymers containing said moieties, with the most preferred being salvianolic acid dimers, trimers, tetramers and larger polymers. The compounds and compositions may be administered in pharmaceutically acceptable carriers and excipients systemically or locally to treat viral infections.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 28, 2000
    Assignee: Georgetown University School of Medicine
    Inventors: Myun K. Han, Paul Lee
  • Ligand growth factor gp30 that binds to the erbB-2 receptor protein and induces cellular responses
    Patent number: 6040290
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: March 21, 2000
    Assignee: Georgetown University
    Inventors: Marc E. Lippman, Ruth Lupu
  • Compounds obtained from salvia species having antiviral Activity
    Patent number: 6037369
    Abstract: The instant invention provides compositions containing molecules having at least one moiety from .beta.(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid which are found in extracts from genus Salvia, said moieties being of the formula: ##STR1## said active agents having a molecular weight of at least 190 daltons. A class of preferred agents are those which are conjugated to form dimers and larger polymers containing said moieties. The agents of the invention may be administered in pharmaceutically acceptable carriers systemically or locally.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: March 14, 2000
    Assignee: Georgetown University School of Medicine
    Inventors: Myun K. Han, Paul Lee
  • Treatment of emphysema with retinoic acid or other retinoids by inducing formation of gas-exchange units (alveoli)
    Patent number: 5998486
    Abstract: This invention relates to the use of retinoic acid, its esters and analogues thereof, for treatment of emphysema. The method comprises administration of a composition containing an effective amount of a retinoic acid, or an ester or an analoge thereof, to induce alveolar formation.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: December 7, 1999
    Assignee: Georgetown University School of Medicine
    Inventors: Gloria Massaro, Donald Massaro
  • Extracts of salvia species having antiviral activity
    Patent number: 5994400
    Abstract: This invention provides extracts of Salvia species essentially consisting of that fraction from a Salvia that precipitates from aqueous solution at pH .ltoreq.3, said precipitate having the property such that it is is essentially fully dissolved in aqueous solution at pH 6, with solubility beginning to be readily observable at about pH 4, said extract having a molecular weight of .ltoreq.3500 datons. A preferred embodiment of the invention provides active agents having a molecular weight of .ltoreq.1000 daltons.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 30, 1999
    Assignee: Georgetown University School of Medicine
    Inventors: Myun K. Han, Paul Lee